SENTARA COMMUNITY PLAN
(MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Orencia® SQ (abatacept) **(Pharmacy)**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

DIAGNOSIS	RECOMMENDED DOSE
❑ **Moderate to severe Active Rheumatoid Arthritis (RA)** ❑ **Psoriatic Arthritis (PsA)**	**SUBCUTANEOUS** • 125 mg once a week (4 syringe/28 days) **Pediatric dosing:** • **Weighing 10 kg to less than 25 kg:** 50 mg once a week (1 syringe/28 days) • **Weighing 25 kg to less than 50 kg**: 87.5 mg once a week (1 syringe/28 days) • **Weighing 50 kg or greater:** 125 mg once a week (4 syringes/28 days)

(Continued on next page)

DIAGNOSIS	RECOMMENDED DOSE
❑ **Juvenile Idiopathic Arthritis (pJIA) in members 2 years and older**	**SUBCUTANEOUS** • **Weighing greater 50 kg**: 125 mg once a week (4 syringes/28 days) • **Weighing 25 kg to less than 50 kg:** 87.5 mg (Four syringes of 87.5mg/28days) once a week • **Weighing 10kg to 25 kg**: 50 mg once a week (Four syringes of 50 mg/28 days)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Diagnosis - Check applicable diagnosis below

❑ Moderate to severe Active Rheumatoid Arthritis (RA)

- ❑ Member is 18 years of age or older
- ❑ Member has been diagnosed with moderate to severe rheumatoid arthritis
- ❑ Trial and failure of one conventional synthetic disease modifying anti-rheumatic drug (csDMARD) (e.g. methotrexate, azathioprine, hydroxychloroquine, penicillamine, sulfasalazine, leflunomide, etc.)
- ❑ Trial and failure of **BOTH** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®

❑ Polyarticular Juvenile Idiopathic Arthritis (pJIA)

- ❑ Member is 2 years of age or older
- ❑ Member has been diagnosed with moderate to severe active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
- ❑ Trial and failure of either oral non-steroidal anti-inflammatory drugs (NSAIDs) OR one conventional synthetic disease modifying anti-rheumatic drug (csDMARD) (e.g. methotrexate, azathioprine, hydroxychloroquine, penicillamine, sulfasalazine, leflunomide, etc.)
- ❑ Trial and failure of **BOTH** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®

(Continued on next page)

❑ Active Psoriatic Arthritis (PsA)

- ❑ Member is 2 years of age and older
- ❑ Member has been diagnosed with moderate to severe active Psoriatic Arthritis (PsA)
- ❑ Trial and failure of **TWO (2)** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®	❑ Pyzchiva® **OR** Starjemza™ syringe/vial (Requires trial and failure of a preferred TNF-alpha inhibitor)

Medication being provided by (check applicable box(es) below):

❑ **Physician's office** **OR** ❑ **Specialty Pharmacy – PropriumRx**

For urgent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

REVISED/UPDATED/REFORMATTED: ~~8/1/2017; 12/20/2017; 6/4/2018; 8/28/2018; 10/8/2018; 12/9/2018; 4/6/2019; 7/19/2021; 1/6/2022; 6/29/2022; 7/13/2022; 6/20/2023, 11/10/2023; 6/07/2024, 10/17/2025; 12/14/2025, 2/23/2026; 3/12/2026;~~ **7/14/2026**